• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by SAB Biotherapeutics Inc.

    8/5/25 5:08:39 PM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SABS alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
       None
    Entity Type
    0001833214
    Big Cypress Acquisition Corp.
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    SAB Biotherapeutics, Inc.
    Jurisdiction of Incorporation/Organization
    DELAWARE
    Year of Incorporation/Organization
       Over Five Years Ago
    X Within Last Five Years (Specify Year) 2020
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    SAB Biotherapeutics, Inc.
    Street Address 1 Street Address 2
    777 W 41st St Suite 401
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    Miami Beach FLORIDA 33140 305 845-2813

    3. Related Persons

    Last Name First Name Middle Name
    Reich Samuel
    Street Address 1 Street Address 2
    777 W 41st St Suite 401
    City State/Province/Country ZIP/PostalCode
    Miami Beach FLORIDA 33140
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Sullivan Eddie
    Street Address 1 Street Address 2
    777 W 41st St Suite 401
    City State/Province/Country ZIP/PostalCode
    Miami Beach FLORIDA 33140
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Ellias Katie
    Street Address 1 Street Address 2
    777 W 41st St Suite 401
    City State/Province/Country ZIP/PostalCode
    Miami Beach FLORIDA 33140
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Giberson Scott
    Street Address 1 Street Address 2
    777 W 41st St Suite 401
    City State/Province/Country ZIP/PostalCode
    Miami Beach FLORIDA 33140
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Hamilton Christine
    Street Address 1 Street Address 2
    777 W 41st St Suite 401
    City State/Province/Country ZIP/PostalCode
    Miami Beach FLORIDA 33140
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Link David
    Street Address 1 Street Address 2
    777 W 41st St Suite 401
    City State/Province/Country ZIP/PostalCode
    Miami Beach FLORIDA 33140
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Lucera Erick
    Street Address 1 Street Address 2
    777 W 41st St Suite 401
    City State/Province/Country ZIP/PostalCode
    Miami Beach FLORIDA 33140
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Moin Andrew
    Street Address 1 Street Address 2
    777 W 41st St Suite 401
    City State/Province/Country ZIP/PostalCode
    Miami Beach FLORIDA 33140
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Polvino William
    Street Address 1 Street Address 2
    777 W 41st St Suite 401
    City State/Province/Country ZIP/PostalCode
    Miami Beach FLORIDA 33140
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Skyler Jay
    Street Address 1 Street Address 2
    777 W 41st St Suite 401
    City State/Province/Country ZIP/PostalCode
    Miami Beach FLORIDA 33140
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Spragens Jeffrey
    Street Address 1 Street Address 2
    777 W 41st St Suite 401
    City State/Province/Country ZIP/PostalCode
    Miami Beach FLORIDA 33140
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
    X Biotechnology
       Health Insurance
       Hospitals & Physicians
       Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2025-07-21    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

    X Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
    X Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
       Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security    Other (describe)

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number    None
    Leerink Partners LLC 39011
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    None None
    Street Address 1 Street Address 2
    53 STATE STREET 40TH FLOOR
    City State/Province/Country ZIP/Postal Code
    BOSTON MASSACHUSETTS 02109
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US
    CALIFORNIA
    ILLINOIS
    MASSACHUSETTS
    NEW JERSEY
    NEW YORK

    Recipient
    Recipient CRD Number    None
    UBS SECURITIES LLC 7654
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    None None
    Street Address 1 Street Address 2
    1285 AVENUE OF THE AMERICAS
    City State/Province/Country ZIP/Postal Code
    NEW YORK NEW YORK 10019
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US
    CALIFORNIA
    ILLINOIS
    MASSACHUSETTS
    NEW JERSEY
    NEW YORK

    Recipient
    Recipient CRD Number    None
    Oppenheimer & Co. Inc. 249
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    None None
    Street Address 1 Street Address 2
    85 BROAD STREET 22ND,24TH FLOOR
    City State/Province/Country ZIP/Postal Code
    NEW YORK NEW YORK 10004
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US
    CALIFORNIA
    ILLINOIS
    MASSACHUSETTS
    NEW JERSEY
    NEW YORK

    Recipient
    Recipient CRD Number    None
    Chardan Capital Markets, LLC 120128
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    None None
    Street Address 1 Street Address 2
    1 PENNSYLVANIA PLAZA SUITE 4800
    City State/Province/Country ZIP/Postal Code
    NEW YORK NEW YORK 10019
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US
    CALIFORNIA
    ILLINOIS
    MASSACHUSETTS
    NEW YORK

    13. Offering and Sales Amounts

    Total Offering Amount $175,000,000 USD
    or    Indefinite
    Total Amount Sold $175,000,000 USD
    Total Remaining to be Sold $0 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    17

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $10,500,000 USD
       Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    SAB Biotherapeutics, Inc. /s/ Samuel J. Reich Samuel J. Reich Chief Executive Officer 2025-08-05

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $SABS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SABS

    DatePrice TargetRatingAnalyst
    5/14/2025$10.00Buy
    H.C. Wainwright
    10/9/2024$11.00Buy
    Craig Hallum
    8/28/2024$12.00Outperform
    Oppenheimer
    11/5/2021$17.00Buy
    Chardan Capital Markets
    11/2/2021$23.00Outperform
    Robert W. Baird
    11/2/2021$23.00Outperform
    Baird
    More analyst ratings

    $SABS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Sessa Capital (Master), L.P.

    4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)

    7/24/25 4:31:07 PM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Moin Andrew

    4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)

    7/24/25 4:30:04 PM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CHIEF MEDICAL OFFICER Kropotova Alexandra covered exercise/tax liability with 1,179 shares, decreasing direct ownership by 2% to 47,249 units (SEC Form 4)

    4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)

    4/1/25 4:19:49 PM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SABS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Sullivan Eddie Joe bought $1,531 worth of shares (1,740 units at $0.88), increasing direct ownership by 0.03% to 5,232,304 units (SEC Form 4)

    4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)

    12/8/23 8:00:05 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    King Michael bought $4,500 worth of shares (5,000 units at $0.90) (SEC Form 4)

    4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)

    11/30/23 5:00:07 PM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Reich Samuel J bought $9,842 worth of shares (11,000 units at $0.89), increasing direct ownership by 5% to 219,001 units (SEC Form 4)

    4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)

    11/30/23 8:00:04 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SABS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates

    Recently raised $175 million in oversubscribed private placement which included strategic investor Sanofi and top-tier biotech investors Strong cash position with completed financing extending operational runway until the middle of 2028 Achieved alignment with FDA on the design and advancement of Phase 2b SAFety and Efficacy of human anti-thymocyte immunoGlobUlin SAB-142 ARresting progression of type 1 Diabetes (SAFEGUARD) study following a constructive Type B meeting SAFEGUARD study to initiate in Q3 2025 MIAMI, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), ("SAB BIO" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platfor

    8/7/25 7:30:00 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SAB BIO Announces Oversubscribed $175 Million Private Placement

    Participation from strategic investor Sanofi, along with new investors RA Capital Management, Commodore Capital, Vivo Capital, Blackstone Multi-Asset Investing, Spruce Street Capital, Forge Life Science Partners and Woodline Partners LP, and existing investors Sessa Capital, the T1D Fund, and ATW Partners Proceeds expected to fully fund completion of pivotal Phase 2b SAFEGUARD study evaluating SAB-142 for delaying progression of autoimmune T1D in newly diagnosed T1D patients (Stage 3) Company expects proceeds to extend cash runway into the middle of 2028 Potential for up to an additional $284 million of gross proceeds if milestone-based warrants exercised in full MIAMI, July 21, 2025 (

    7/21/25 7:30:00 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates

    MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), ("SAB BIO" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced financial results for the quarter ending March 31, 2025, and reported on recent developments. Samuel J. Reich, Chairman and CEO of SAB BIO, stated, "We have made strong progress this quarter on our corporate strategy and mission to deliver a transformational therapy that can halt or delay the progression of type 1 diabetes. Based on our recent positive Phase 1 topline data for

    5/9/25 9:00:40 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SABS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on SAB BIO with a new price target

    H.C. Wainwright resumed coverage of SAB BIO with a rating of Buy and set a new price target of $10.00

    5/14/25 9:00:46 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Craig Hallum initiated coverage on SAB BIO with a new price target

    Craig Hallum initiated coverage of SAB BIO with a rating of Buy and set a new price target of $11.00

    10/9/24 8:27:55 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Oppenheimer initiated coverage on SAB BIO with a new price target

    Oppenheimer initiated coverage of SAB BIO with a rating of Outperform and set a new price target of $12.00

    8/28/24 7:53:59 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SABS
    SEC Filings

    View All

    SEC Form PRE 14A filed by SAB Biotherapeutics Inc.

    PRE 14A - SAB Biotherapeutics, Inc. (0001833214) (Filer)

    8/19/25 4:30:03 PM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by SAB Biotherapeutics Inc.

    10-Q - SAB Biotherapeutics, Inc. (0001833214) (Filer)

    8/7/25 7:30:52 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form D filed by SAB Biotherapeutics Inc.

    D - SAB Biotherapeutics, Inc. (0001833214) (Filer)

    8/5/25 5:08:39 PM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SABS
    Leadership Updates

    Live Leadership Updates

    View All

    SAB BIO Reports Full Year 2024 Operating and Financial Results

    MIAMI, March 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), ("SAB BIO" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced financial results for the fourth quarter of 2024 in addition to its full year financial results for the fiscal year ended December 31, 2024, and reported on recent accomplishments and anticipated milestones. Samuel J. Reich, Chairman and CEO of SAB BIO stated, "Our recent announcement of positive topline data for SAB-142, further strengthens our belief that SAB-142 has the pote

    3/31/25 7:32:00 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates

    FDA provided clearance to SAB's IND Appointed Lucy To as Chief Financial Officer Announced founding of a new Clinical Advisory Board MIAMI, Aug. 08, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today reported financial results for the second quarter ended June 30, 2024, and provided a company update. "We've had a strong quarter as we drive closer to our upcoming SAB-142 milestones. We continue to see an urgent need for transformative therapies in this spa

    8/8/24 5:51:04 PM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SAB BIO Appoints Lucy To as Chief Financial Officer

    MIAMI, July 31, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that Lucy To has been named Chief Financial Officer effective August 12, 2024. Ms. To brings over 18 years of investment banking and strategic operational expertise to SAB and will lead corporate finance, corporate strategy and approach to broader strategic business relationships at the company. "Lucy's proven track record and experience will prove invaluable t

    7/31/24 7:30:00 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SABS
    Financials

    Live finance-specific insights

    View All

    SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142

    SAB-142 was generally well-tolerated among healthy volunteers; data from Phase 1 trial confirms SAB-142 does not cause serum sickness or anti-drug antibodies at target dose Study results support that SAB-142 is well-positioned for re-dosing in outpatient setting for type 1 diabetesResults will be presented in an R&D webinar event today at 8:00 am ET; registration details below MIAMI, Jan. 28, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), ("SAB BIO" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today an

    1/28/25 7:00:00 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy

    MIAMI, Jan. 23, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), announced today that the Company will host a Research and Development webinar on January 28, 2025 to discuss the topline data for Phase 1 clinical trial for its lead candidate, SAB-142. The webinar will feature presentations from SAB BIO's management team and T1D Key Opinion Leader (KOL) Michael Haller, MD, the division chief of the Pediatric Endocrinology Division at the University of Florida and S

    1/23/25 7:00:00 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results

    Sioux Falls, SD , March 29, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results March 29, 2024 SAB-142 Phase 1 trial on track for data release during 2024 Completed financing for up to $110 million with leading life science investors Cash and equivalents of $56.6 million as of December 31, 2023 Company expects its cash and equivalents, with exercise of Tranche B warrants, will fund operations into 2026 Sioux Falls, SD March 29, 2024 (GlobeNewswire)—SAB Biotherapeutics, Inc. (NASDAQ:SABS), ("SAB" or "the company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immun

    3/29/24 7:15:00 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SABS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by SAB Biotherapeutics Inc. (Amendment)

    SC 13G/A - SAB Biotherapeutics, Inc. (0001833214) (Subject)

    2/14/24 4:05:33 PM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by SAB Biotherapeutics Inc.

    SC 13G - SAB Biotherapeutics, Inc. (0001833214) (Subject)

    2/14/24 7:02:03 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by SAB Biotherapeutics Inc. (Amendment)

    SC 13G/A - SAB Biotherapeutics, Inc. (0001833214) (Subject)

    2/14/24 6:28:12 AM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care